

1085

PCT/EP 00 / 05358



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

09. Juni 2000

EP00/5358

EJU

REC'D 26 JUN 2000

WIPO PCT

Bescheinigung

Certificate

Attestation

10/018325

HA

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

99111334.1

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts:
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

18/04/00

THIS PAGE BLANK (USPTO)



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.: 99111334.1
Demande n°:

Anmeldetag:
Date of filing: 10/06/99
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
80539 München.
GERMANY

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:

Encapsulation of crystals via multilayer coatings

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:

C30B29/58, A61K9/50, C12N11/04

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

10-06-1999

EP99111334.1

DESC

Cx. 1

PATENTANWÄLTE

European Patent Attorneys
European Trade Mark Attorneys

Dipl.-Ing. H. WEICKMANN
Dipl.-Ing. F. A. WEICKMANN
Dipl.-Chem. B. HUBER
Dr.-Ing. H. LISKA
Dipl.-Phys. Dr. J. PRECHTEL
Dipl.-Chem. Dr. B. BÖHM
Dipl.-Chem. Dr. W. WEISS
Dipl.-Phys. Dr. J. TIESMEYER
Dipl.-Phys. Dr. M. HERZOG
Dipl.-Phys. B. RUTTENSBERGER

POSTFACH 860 820
81635 MÜNCHEN

KOPERNIKUSSTRASSE 9
81679 MÜNCHEN

TELEFON (089) 45563 0

TELEX 522 621

TELEFAX (089) 45563 999

E-MAIL email@weickmann.de

10. Juni 1999

Our Ref.:
20077P EP/WWMDBBclmh

EPO - Munich
55

10. Juni 1999

Applicant:
Max-Planck-Gesellschaft zur
Förderung der Wissenschaften e.V.
Hofgartenstraße 8

80539 Munich
DE

Encapsulation of crystals via multilayer coatings

10. Juni 1999

- 1 -

Encapsulation of crystals

Specification

5

The invention refers to a new process for preparing coated crystals by coating crystal template particles with alternating layers of oppositely charged polyelectrolytes and/or nanoparticles.

- 10 The area of thin film fabrication, in which ordered, functional supramolecular structures are the chief goal, has been greatly impacted by the recent introduction of the layer-by-layer (LbL) self-assembly technique (Decher, Science, 1997, 277, 1232). The LbL method permits the fabrication of multilayer thin film assemblies on solid supports by the
- 15 spontaneous sequential adsorption of oppositely charged species from dilute aqueous solutions onto charged substrates. The driving force for the multilayer film build-up is primarily due to the electrostatic attraction and complex formation between the charged species deposited. The LbL approach was initially employed to construct multilayer films of
- 20 polyelectrolytes (Decher, Science 1997, 277, 1232), and subsequently extended to include proteins (Lvov et al, J. Am. Chem. Soc. 1995, 117, 6117; Onda et al, T. Biotech. Bioeng. 1996, 51, 163; Caruso et al, Langmuir 1997, 13, 3427), nucleic acids (Decher et al, J. Biosens. Bioelectron. 1994, 9, 677; Sukhorukov et al, Thin Solid Films 1996,
- 25 284/285, 220; Caruso et al, Anal. Chem. 1997, 69, 2043), dyes (Araki et al, Langmuir 1996, 12, 5393; Yoo et al, Synthetic Metals 1997, 85, 1425; Ariga et al, J. Am. Chem. Soc. 1997, 119, 2224), dendrimers (Tsukruk et al, Langmuir 1997, 13, 2171), and various inorganic nanoparticles (Kleinfeld et al, Science 1994, 265, 370; Keller et al, J. Am. Chem. Soc. 1994, 116,
- 30 8817; Kotov et al, J. Am. Chem. Soc. 1997, 119, 6821; Kotov et al, J. Phys. Chem. 1995, 99, 13065; Feldheim et al, J. Am. Chem. Soc. 1996, 118, 7640; Schmitt et al, Adv. Mater 1997, 9, 61; Lvov et al, Langmuir

- 2 -

1997, 13, 6195) in polyelectrolyte multilayer assemblies by replacing one of the polyions by a similarly charged species.

The vast majority of studies concerning the LbL technique have employed
5 macroscopically flat charged surfaces as substrates for multilayer film
formation. For example, U.S. 5,716,709 describes multilayered
nanostructures comprising alternating organic and inorganic ionic layers on
a flat substrate, such as a silicon wafer. Recently, Keller et al reported the
preparation of alternating composite multilayers of exfoliated zirconium
10 phosphate sheets and charged redox polymers on (3-aminopropyl)-
triethoxysilane-modified silica particles (Keller et al, J. Am. Chem. Soc.
1995, 117, 12879).

In more recent studies (Caruso et al., *Macromolecules*, 1999, 32, 2317;
15 Caruso et al., *J. Phys. Chem. B*, 1998, 102, 2011; Sukhorukov et al.,
Colloids Surf. A: Physicochem. Eng. Aspects 1998, 137, 253), the LbL
approach was successfully applied to utilise submicron- and micron-sized
charged colloidal particles as the adsorbing substrates to produce colloid-
supported polyelectrolyte multilayer films: regular step-wise polyelectrolyte
20 multilayer growth was observed on the colloids.

Considerable scientific effort has focussed on the fabrication of composite
micro- and nanoparticles that consist of either organic or inorganic cores
coated with shells of different chemical composition (Kawahashi and
25 Matijevic, *J. Colloid Interface Sci.* 1991, 143, 103; Garg and Matijevic,
J. Colloid Interface Sci. 1988, 126; Kawahashi and Matijevic, *J. Colloid
Interface Sci.* 1990, 138, 534; Ohmori and Matijevic, *J. Colloid Interface
Sci.* 1992, 150, 594; Giersig et al., *Adv. Mater.* 1997, 9, 570; Liz-Marzan
et al., *Langmuir* 1996, 12, 4329; Liz-Marzan et al.,
30 *J. Chem. Soc. Chem. Commun.* 1996, 731; Giersig et al.,
Ber. Bunsenges. Phys. Chem. 1997, 101, 1617; Correa-Duarte et al.,
Chem. Phys. Lett. 1998, 286, 497; Bamnolker et al., *J. Mater. Sci. Lett.* 1997,

- 3 -

16, 1412; Margel and Weisel, J. Polym. Sci. Chem. Ed. 1984, 22, 145; Philipse et al., Langmuir 1994, 10, 92). These core-shell particles often exhibit properties which are significantly different to those of the templated core (e.g. different surface chemical composition, increased stability, higher surface area, as well as different magnetic and optical properties), thus making them attractive both from a scientific and technological viewpoint. Applications for such particles are diverse, ranging from capsule agents for drug delivery, catalysis, coatings, composite materials, as well as for protecting sensitive agents such as enzymes and proteins. Previous investigations have demonstrated that polymeric microparticles and inorganic cores can be coated with uniform layers of various materials, including silica, yttrium basic carbonate, zirconium hydrous oxide, either by controlled surface precipitation reactions on the core particles or by direct surface reactions.

U.S. Patent 5,705,222 discloses a process for preparing composite particle dispersions wherein a plurality of core particles is dispersed in a first solution wherein the core particles do not irreversibly self-flocculate, an amount of polymer is added to the dispersion of core particles, wherein the polymer has an affinity for the dispersed core particles and the excess polymer is removed by a solid/liquid separation process, i.e. centrifugation or decanting.

In DE 198 12 083.4 it was suggested that soluble colloidal cores can be used as templates for the sequential deposition of polyelectrolytes to fabricate novel three-dimensional hollow polymer shells. From PCT/EP99/01854 the preparation of coated capsules and hollow shells by coating colloidal particles with alternating layers of oppositely charged nanoparticles and polyelectrolytes is known. DE 199 075 52.2 discloses a process for preparing capsules having a polyelectrolyte shell wherein the template particles are selected from aggregates of biological and/or

- 4 -

amphiphilic materials such as cells, cell aggregates, subcellular particles, virus particles and aggregates of biomolecules.

5 The coating of biocrystals, however, represents several challenges which are not applicable when templating other solid core particles including biological templates. First, the crystals are formed under delicate solution conditions, hence suitable conditions have to be found which facilitate polymer multilayer deposition on the crystal surface and do not destroy the crystal morphology (i. e. to avoid its solubilization), and second, the
10 permeability of the polymer capsule walls must be such that it permits encapsulation of the bio-crystal. In addition, since the primary usefulness of biological molecules is their biological function, their activity should be preserved when encapsulated.

15 Herein we report successful coating of crystals, e. g. bio-crystals by depositing alternating layers of oppositely charged polyelectrolytes and/or nanoparticles on crystal template particles via the sequential electrostatic adsorption of polyelectrolyte and/or nanoparticles from solution. Functional biomolecules are obtainable after solubilization within the
20 polyelectrolyte/nanoparticle shell and/or after removal of the shell.

Thus, a first aspect of the present invention is a process for preparing coated crystals comprising the steps:

- (a) providing a dispersion of crystal template particles in a solvent and
- 25 (b) coating said particles with a multilayer comprising alternating layers of oppositely charged polyelectrolytes and/or nanoparticles.

Suitable crystal template particles are particles of crystallized substances. Preferably the crystals are particles of crystallized organic compounds
30 and/or particles of crystallized biomolecules (bio-crystals) (including molecules which occur in living organisms and/or which influence the metabolism of living organisms). E. g. the crystals may be selected from

- 5 -

crystals of proteins, peptides, nucleic acids, lipids, carbohydrates, saccharides, drugs etc., whereas protein crystals are preferred. Examples of protein crystals are crystals of antibodies, enzymes, such as oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases, virus capsid protein crystals, peptide crystals, S-layer protein crystals, glycoprotein crystals, receptor protein crystals and cytosolic protein crystals. The proteins may be natural, recombinant and/or synthetic proteins. Examples of nucleic acid crystals are crystalline DNA, crystalline RNA and crystalline oligonucleotides. Examples of crystalline low molecular weight materials are crystalline drugs, crystalline vitamins, crystalline nutrients, crystalline hormones and crystalline organic or inorganic salts.

It is also possible to use crystal template particles from crystalline biomaterial, crystalline organic material, crystalline inorganic material or mixtures thereof. Examples of crystalline organic material are crystalline drugs, vitamins, nutrients, hormones, growth factors, pesticides and antibiotics.

The crystalline template particles may be derived from a single crystal or an amorphous crystal material. Suitable crystal template particles may be obtained, for example, from natural sources, may be prepared recombinantly, synthetically or by a cell culture or may be a PCR product.

Preferably, the template particles have an average diameter of up to 500 μm , in particular, $\leq 50 \mu\text{m}$, more particularly $\leq 10 \mu\text{m}$, more preferably $\leq 5 \mu\text{m}$, and most preferably $\leq 2 \mu\text{m}$. The minimum diameter of the template particles is preferably 10 nm, more preferably 100 nm, most preferably 200 nm and, in particular, 1 μm . The structure or shape of the template may be in any desired form, e. g. rectangular, square, spherical, triangular and various other forms depending on the structure of the crystal to be templated.

- 6 -

Important advantages of the crystal templating procedure presented are its versatility and generality. The thickness of the polymer walls can be controlled by varying the number of polyelectrolyte/nanoparticle deposition cycles, thus providing a straightforward and simple means to vary the permeability of the capsules. It can also be used to encapsulate biological materials in crystalline form in order to perform chemical reactions, e.g. enzymatic reactions. Furthermore, the entire volume of the capsule consists of an active biomolecule, making the activity per volume of the encapsulated biomolecule several orders of magnitude higher than that of conventional or immobilized biomolecules. This has the advantage of reducing the reaction times and the volume of biomolecule required, and maximizes activity and productivity. The multilayer coating also provides a way to preserve and/or prolong the activity of the encapsulated biomolecules by protecting them in environments where certain substances, e. g. macromolecules, degrading enzymes, e.g. proteases, nucleases, etc., microorganisms, inhibitors etc. may cause their degradation.

The successful encapsulation of bio-crystals by the nanoscale engineering of polymer capsules on bio-crystal templates as demonstrated here, coupled with the easy diffusion of small mobile substrates and reaction products through the polymer walls, is a promising way to both control and increase the efficiency of catalytic processes. Combining these templating process with recently developed techniques that allow the layering of various enzyme layers on colloids yields enzyme nanoreactor systems for sequential biocatalytic reactions. Columns packed with the biocrystal loaded capsules can be used for chromatographic separations and - in the case of encapsulated enzymes - as catalytic converters. Further, the introduction of functionalities, e. g. magnetic properties, by incorporation of suitable nanoparticles in the polymer walls provides a multifunctional system with a plurality of properties. Together, these developments provide outstanding opportunities to produce tailored and optimized systems for numerous applications in the biotechnology area.

- 7 -

The process according to the present invention comprises coating the template particles with coatings of polyelectrolyte molecules and/or nanoparticles. The polyelectrolytes are usually polymers having ionically dissociable groups which may be a component or substituent of the polymer chain. Preferably, linear or/and water soluble polyelectrolytes are used. However, polyelectrolytes being non-linear polymers or mixtures of linear and non-linear polymers also can be used. Depending on the type of dissociable group, polyelectrolytes are subdivided into polyacids and polybases. Upon dissociation polyacids separate protons to give polyanions. Examples of polyacids are polyphosphoric acid, polyvinyl or polystyrene sulphuric acid, polyvinyl or polystyrene sulfonic acid, polyvinyl or polystyrene phosphonic acid and polyacrylic acid. Examples of the respective salts which are also called polysalts, are polyphosphate, polysulphate, polysulfonate, polyphosphonate and polyacrylate.

Polybases contain groups which are capable of accepting protons, e.g. by reacting with acids to give salts. Examples of polybases are polyamines, such as polyethylene amine, polyvinyl amine and polyvinyl pyridine or poly(ammonium salts), such as poly (diallyl dimethylammonium chloride). Polybases form polycations by accepting protons.

The polyelectrolytes may be or may be based on organic polymers, inorganic polymers and biopolymers or mixtures thereof. Preferred examples of organic polymers are biodegradable polymers such as polyglycolic acid (PGA), polylactic acid (PLA), polyamides, poly-2-hydroxy butyrate (PHB), polycaprolactone (PCL), poly(lactic-co-glycolic) acid (PLGA) and copolymers thereof. Further preferred examples of organic polymers are labelled polymers, e.g. fluorescently labelled polymers, conducting polymers, liquid crystal polymers, photoconducting polymers and photochromic polymers as well as copolymers thereof.

- 8 -

Preferred examples of suitable biopolymers are poly amino acids such as peptides or S-layer proteins, poly carbohydrates such as dextrans, pectins, alginates, glycogens, amyloses or chitins, polynucleotides, e. g. DNA, RNA, oligonucleotides, gelatins (gelatin A, gelatin B) or modified biopolymers, e.
5 g. carboxymethyl cellulose, carboxymethyl dextran or lignin sulfonates.

Preferred examples of suitable inorganic polymers, based on which the polyelectrolytes can be created, are polysilanes and silanoles, polyphosphazenes, polysulfazenes and polysulfides and polyphosphates.
10

The polyelectrolytes can be cross-linked after templating. The cross-linking can be done between the polymers in one layer or/and between polymers of different layers.

15 The nanoparticles preferably have an average diameter from 1 to 100 nm, more preferably from 5 to 50 nm and most preferably from 10 to 20 nm. The structure or shape of the nanoparticle may be in any desired form, with the most preferable shape being spherical and/or monodisperse.

20 The nanoparticles may be selected from inorganic, organic and biological materials. Preferred examples of inorganic particles are ceramic particles, e.g. oxidic ceramic particles, such as silicon dioxide, titanium dioxide, zirconium dioxide optionally doped with other metal oxides, magnetic particles such as iron oxide-containing particles such as Fe_3O_4 , magneto-optical particles, nitridic ceramic particles, e.g. Si_3N_4 , carbidic ceramic particles, metallic particles, e.g. gold, silver, palladium and sulfur or seleno-
25 containing particles such as cadmium sulfide, cadmium selenide etc. Especially preferred are particles having magnetic properties. Examples of organic or biological nanoparticles are macromolecules, such as
30 polypeptides, proteins, nucleic acids, enzymes, antibodies, receptor/ligand systems etc. and targeting molecules for therapeutical applications. Especially preferred biological nanoparticles are proteins, e.g.

- 9 -

immunologically reactive proteins such as antigens and antibodies, e.g. IgG, or targeting molecules for therapeutical applications. Further, the biological nanoparticles may be deposited as conjugates containing a labelling group, e.g. a fluorescent group such as fluorescein. The resulting particles are suitable for analytical, e.g. immunological, detection methods. Further, an immobilization of enzymes, single enzymes or a plurality of enzymes, e.g. members of an enzymatic cascade, in single layers or different layers is of special interest because of the ability to increase the catalysis efficiency. Substrates could readily diffuse through the film and react with the immobilized enzyme, thereby producing product.

For the preparation of the coated particles according to the present application a dispersion of crystal template particles in suitable solvent is provided. A suitable solvent is a solvent where the crystal may be encapsulated. In some cases the solvent is an aqueous solvent. In other cases the solvent may be a mixture of an aqueous solvent with organic solvents. Still in other cases the solvent may be a pure organic solvent. Among the organic solvents polar solvents are preferred, e.g. polar protic solvents such as alcohols or polar aprotic solvents such as esters. Preferred examples of aqueous solvents are aqueous buffers which optionally contain detergents and/or antifoaming and/or antimicrobial agents. Aqueous solvents preferably contain buffer salts for pH and/or ionic strength adjustment. Preferred examples of mixed solvents are mixtures of water or aqueous buffers with polar protic organic solvents such as alcohols, organic acids, amines, pyridin or mercaptanes or mixtures of water or buffer with polar aprotic organic solvents such as ketones, esters, ethers, ethyleneglycols, nitriles, formamide, alkylated formamides, nitroalkanes and dialkylsulfoxides. Preferred examples of organic solvents are polar protic organic solvents such as alcohols, organic acids, amines, pyridines, mercaptanes or mixtures thereof and polar aprotic organic solvents such as ketones, esters, ethers, ethyleneglycols, nitriles, formamide, alkylated

- 10 -

formamides, nitroalkanes, dialkylsulfoxides and mixtures thereof. Of course also mixtures of protic and aprotic solvents may be used.

The dispersion of the template particles in the solvent may contain a salt, e.g. NaCl or KAc in a concentration which preferably ranges from 50 mmole/l to 1 mole/l. The solvent, pH, the temperature and the salt concentration in the dispersion are adjusted that the respective crystal template particles which are to be encapsulated are not substantially dissolved. Encapsulation temperatures of from 0°C to 10°C, e. g. 4°C are preferred. E. g., the encapsulation of catalase enzyme crystals may be carried out in an aqueous solution of 1 M potassium acetate, pH 5, 4°C. Alternating layers of oppositely charged components, i.e. polyelectrolyte molecules and/or nanoparticles, different types of nanoparticles or combinations thereof are then deposited on said template particles. The pH of the dispersion is adjusted in such a way that the molecules, e.g. polyelectrolyte molecules and nanoparticles, each have opposite total charges, thus facilitating their deposition via electrostatics. The thickness of the coating which is determined by the number of layers is preferably 2 to 1000 nm, with 2 to 40 and particularly 2 to 20, e.g. 3 to 10 coatings being applied. Suitably, each layer may be comprised of a single species of polyelectrolyte and/or nanoparticle or of a mixture comprising at least two polyelectrolyte and/or nanoparticle species. Further, for each layer different polyelectrolyte and/or nanoparticle species may be used.

After application of each layer the excessive molecules (e.g. polyelectrolyte and/or nanoparticle) which have not contributed to forming the layer are preferably separated off before the next layer is applied. Such separation can be done according to any known method, particularly centrifugation, filtration and/or dialysis.

In a preferred embodiment of the invention the template particles are at first coated with several layers of oppositely charged cationic and anionic

- 11 -

polyelectrolytes before the alternating layers of nanoparticles and polyelectrolyte or the alternating nanoparticle layers are applied. The coating of template particles with several layers of oppositely charged polyelectrolytes is described in DE 198 12 083.4 to which express
5 reference is made. Preferably, the template particles are coated with at least two and up to six layers of oppositely charged cationic and anionic polyelectrolytes, e.g. with three layers. The outermost polyelectrolyte layer is preferably oppositely charged with regard to the polyelectrolyte/nanoparticle to be deposited.

10 The thickness of the shell walls around the template particles can be readily controlled by varying the number of deposition cycles, whilst the shell size and shape are predetermined by the dimensions of the template particle employed. The thickness of the shell can vary in a wide range, e.g. from 2
15 to 1000 nm, particularly from 5 to 250 nm. The capsule thickness and permeability for controlled release of encapsulated material can be controlled by the number of layers, by the nature of the polyelectrolytes and/or nanoparticles used and, if desired, by an additional cross-linking step.

20 Excessive molecules, e.g. polyelectrolytes and/or nanoparticles which do not contribute to forming the layers may be separated after each templating step. The separation can be done, e.g. by centrifugation, filtration, dialysis or by sorting technologies regarding a special property, such as optical or
25 magnetic properties. By the process of the invention the template crystals may be obtained encapsulated after the templating process.

It is possible to at least partially solubilize the encapsulated crystals after the coating has been completed. The solubilization can be carried out by
30 adjustment of solvent, pH, temperature and/or salt conditions. The solubilized compounds, e. g. biomolecules substantially retain their

- 12 -

functionality, e. g. biological activity after encapsulation and subsequent solubilization.

Further, it was found that the capsule walls can be ruptured or dissolved under conditions which do not significantly impair the activity of the encapsulated biomolecules (as crystals or after solubilization). The capsule walls may be dissolved by adjusting appropriate conditions, such as pH, e. g. under alkaline or acidic conditions, by means of chemical or biochemical degradation, or by physical methods, e. g. ultrasound.

Of particular importance for the use of the coated particles is the permeability of the shell wall. The permeability of the shell wall can be influenced by the selection of the polyelectrolytes used for the shell, the wall thickness and the ambient conditions. It is thus possible to selectively determine and change the permeability properties. Further, the permeability of the shell wall can be influenced by partially dissolving parts of the shell walls, e. g. by using a deproteinizer.

The permeability properties can be further modified by pores in at least one of the layers. Such pores can be formed by the polyelectrolytes or nanoparticles themselves if suitably chosen. By incorporating selective transport systems such as carriers or channels into the polyelectrolyte shell the transversal transport properties of the shell can be adapted to the respective application. The pores or channels of the shell wall can be selectively opened and closed, respectively, by chemically modifying and/or changing the ambient conditions. A high salt concentration of the medium used for the deposition of the polyelectrolyte results in a low packing density and a high permeability of the shell wall. On the other hand, a high salt concentration of the medium used for the deposition of the nanoparticles results in a high packing density. Thus, by adjusting the salt concentrations in the deposition medium, the permeability of the shell can be controlled, as desired. Further, the permeability properties of the shell

- 13 -

may be modified by selecting the conditions for decomposing the core, e.g. by selecting the temperature and heating conditions in a calcination procedure.

5 Still another method to modify the permeability of the shell walls is the deposition of one or several lipid layers on the outside of the shell wall or as an intermediate layer. Furthermore, the permeability may be modified by deposition of S-layer proteins. These proteins are able to build monolayers having a thickness of e. g. 5-20 nm by self-assembling on surfaces. These
10 monolayers have a very defined structure and also a defined pore size of e. g. 4-8 nm. Incorporating such proteins in the capsule wall allows a further control of the capsule permeability properties.

Finally, the templated biomolecules can be at least partially disintegrated
15 after the coating has been completed. They can be disintegrated in appropriate reagents, e. g. deproteinizer solutions or thermally (e.g. by calcination to temperatures of at least 500°C). After dissolution of the biomolecules hollow shells remain which are composed of polyelectrolyte material, nanoparticle material or optionally polyelectrolyte and nanoparticle
20 material. The resulting hollow shells may be inorganic or organic shells or composite inorganic-organic or composite inorganic-inorganic shells depending on the method of core removal. For example, when thermal treatment (calcination) is used, all organic matter is removed, hence only inorganic shells are obtained. Exposure to deproteinizer solutions to remove
25 the core results in polyelectrolyte shells or composite hollow particles in which the core is removed but the polyelectrolyte assembled between the nanoparticle layers remains in the shell.

The hollow shells may be characterized by any known methods, e.g. by
30 scanning and transmission electron microscopy and atomic force microscopy. Preferably, the shells are uniform layers of regular thickness and can find applications in numerous areas, such as medicine,

- 14 -

pharmaceutics, catalysis, optics, magnetics, separation and sensing. In the hollow shells of the present invention active agents, e.g. inorganic or/and organic substances can be encapsulated. Examples of active agents are pharmaceutical agents so that the shells can be used as drug delivery systems in order to transport the active agents to the desired place in the organism. Further, also contrasting agents can be enclosed in the shells, e.g. to improve the quality of images obtained by ultrasonic examination. It is also possible that the hollow shells themselves are used as contrasting agents.

A further aspect of the present invention is a coated crystal particle, preferably a bio-crystal particle having a core which is a template particle and a multilayer shell comprising alternating layers of oppositely charged inorganic polyelectrolytes and/or nanoparticles. Still a further aspect of the present invention is a coated particle having a core comprising an at least partially solubilized crystal template particle, preferably a bio-crystal particle and a multilayer shell comprising alternating layers of oppositely charged polyelectrolytes and/or nanoparticles. Preferably, the average diameter of the coated particle is 15 μm or less, more preferably 100 nm to 10 μm .

Still a further aspect of the present invention is a hollow shell obtainable by disintegrating the template biomolecules of the coated particle as described above. The hollow shell may be an organic structure, an inorganic structure or a composite organic-inorganic structure depending on the method used to remove the core.

The coated particle may be used as a system for targeted delivery and/or controlled release of encapsulated crystallized and/or solubilized substances. Targeting may be accomplished by selecting specific nanoparticles and/or polyelectrolytes for the construction of the multilayer shell which provide specific functional properties allowing targeting of the resulting capsule. Examples of functional nanoparticles are nanoparticles which provide

- 15 -

magnetic properties to the resulting capsules. Further examples of nanoparticles having targeting function are biomolecules such as specific immunoglobulins, receptor ligands etc. Controlled release of the encapsulated crystallized and/or solubilized substances is obtainable by
5 choosing pH swellable, thermally or environmentally responsive and/or biodegradable polyelectrolyte and/or nanoparticle constituents of the capsule wall.

The coated particles may be used to prevent degradation of the
10 encapsulated material, e.g. in the body of animals and humans. It can also be used to control the ability of the encapsulated material to permeate cell walls or bio-membranes. It further can be used to control the immune-reaction of an organism against the encapsulated material by the nature of the capsule material.

15 Further, the invention is illustrated by the following figures and examples:

Figure 1 is a scheme showing an embodiment of the process used to encapsulate biomolecules by using biocrystals as templates for
20 the deposition of polymer multilayers. (1), (2) Polyelectrolyte layers are deposited step-wise onto the biocrystal templates by making use of the surface charge reversal that occurs upon adsorption of each layer. Each polyelectrolyte is removed by repeated centrifugation/wash cycles before the next layer is deposited. (3) Solubilisation of the biomolecule inside the
25 polymer capsule by exposure to solutions of $\text{pH} > 6$ or acidic (approximately $\text{pH} < 4$) solutions in a morphology change of the polymer capsule. (4) Release of the biomolecule by rupturing the polymer capsule may e. g. be achieved by exposure to solutions of $\text{pH} > 11$. (5) Exposure of the
30 encapsulated biomolecule to an oxidising solution results in decomposition of the biomolecule which then is expelled from

- 16 -

the interior through polymer walls, leaving behind hollow polymer capsules that originally encapsulated the biomolecule.

Figure 2 shows images of uncoated and polymer-multilayer coated catalase crystals. a. AFM image of an uncoated crystal showing its essentially square shape and micrometer dimensions. b. Fluorescence optical micrographs of catalase crystals coated with eight $[(PSS/FITC-PAH)_4]$ polyelectrolyte multilayers showing the applicability of the coating process to enzyme crystal templates. The polycation, PAH, deposited in alternation with the polyanion, PSS, is fluorescently labelled with fluorescein isothiocyanate (FITC). No noticeable change in crystal morphology is observed with the polymer multilayer coating.

Figure 3 shows representative optical micrographs of the polymer capsules encapsulating solubilised enzyme. a. A polymer capsule containing solubilized enzyme in its interior. The essentially spherical shape is assumed upon solubilisation of the enzyme as a result of exposure to solutions of $pH > 6$. Solubilization also occurs upon exposure to solutions of $pH < 4$. b. Rupturing of a polymer capsule causes the release of the entrapped, solubilized enzyme. Rupturing is achieved by subjecting the polymer capsules to alkaline solutions of $pH > 11$.

Figure 4 shows micrographs of air-dried hollow polymer capsules obtained after decomposition of the encapsulated enzyme. a. AFM image of a polymer capsule comprising eight $[(PSS/PAH)_4]$ polyelectrolyte layers. The polymer capsule spreads out on the glass surface on which it is dried and folds and creases in the shell can be seen. Some undecomposed

- 17 -

enzyme can still be seen in the interior of the capsule. The z range (height) of the image is 650 nm. b. TEM image also shows folds and creases as well as the presence of a small amount of residual enzyme inside the capsule.

1. Methods

1.1 Catalase crystal encapsulation

The catalase enzyme crystals (Sigma, C-100) were washed twice with a chilled (4°C) solution of 1 M potassium acetate at pH 5 (buffer), with intermittent centrifugation steps (500 g, 4 min, 4°C) to remove the supernatant, prior to polymer coating. The polymer layers were assembled onto the enzyme crystals by the alternate deposition of poly(sodium 4-styrenesulfonate) (PSS), M_w 70,000 and poly(allylamine hydrochloride) (PAH), M_w 8,000-11,000, both obtained from Aldrich. PSS was dialyzed against water and lyophilized before use. The first layer was deposited by adding a 0.5 ml aliquot of a 5 mg/ml aqueous PSS solution (containing 1 M potassium acetate, pH 5, 4°C) to 0.2 ml of the crystal suspension, occasionally shaking the suspension, and allowing 25 min for adsorption. The excess polyelectrolyte was removed by 3 repeated centrifugation (500 g, 4 min, 4°C)/chilled buffer wash/redispersion cycles. The next layer, PAH, was deposited from a 5 mg/ml solution containing 1 M potassium acetate (pH 5 at 4°C) using the same procedure and conditions. Subsequent alternating PSS and PAH layers were deposited in identical fashion until the desired number of polymer multilayers was achieved. Hollow polymer capsules were obtained by exposing the polymer multilayer-coated capsules to a deproteinizer solution (Medical Instruments). The deproteinizer destroys the protein.

- 18 -

1.2 Determination of catalase activity

The enzyme was released from the polymer capsules by exposure to ultrasound for 5 min at 20°C in 1 M phosphate buffer at pH 7 (this caused rupturing of the polymer walls). The catalase activity was determined using a standard enzyme activity assay (Biochemica Information, 15-16 Boehringer Mannheim (1987); Tijssen, Practice and Theory of Enzyme Immunoassays, 8th Impression (1993), Elsevier, 202-203): that is, by measuring the decomposition of the substrate hydrogen peroxide (H_2O_2) at 240 nm. The concentration of the catalase was determined spectrophotometrically at 280 nm and 405 nm (soret band). The specific activity of the uncoated catalase was measured in the same way and used for comparison.

1.3 Electrophoretic mobility and microscopy measurements

Electrophoretic mobilities of the uncoated and polymer-multilayer coated enzyme crystals were measured using a Malvern Zetasizer 4 as described elsewhere (Caruso et al., J. Phys. Chem. B 102, 2011 - 2116 (1998); Sukhorukov, G. B. et al., Polym. Adv. Technol. 9, 759 - 767 (1998); Donath et al., Angew. Chem. Int. Ed. 37, 2201 - 2205 (1998). The mobility u was converted into a ξ -potential using the Smoluchowski relation $\xi = u\eta/\epsilon$, where η and ϵ are the viscosity and permittivity of the solution, respectively. Atomic force microscopy (AFM) images were obtained using a Digital Instruments Nanoscope IIIa AFM in tapping mode (TM) on samples deposited onto cleaned glass slides and air-dried. Samples for transmission electron microscopy (TEM) were prepared by deposition of aqueous solutions of the hollow polymer capsules upon a carbon-coated copper grid, allowing them to air dry for one minute, and then blotting off the extra solution.

- 19 -

2. Results

The basic approach using enzyme crystals as templates for encapsulation by polymer multilayers is illustrated in Fig. 1. The method takes advantage of the fact that catalase is a crystalline suspension in water at pH 5-6 and therefore can be treated as a colloidal particle. The catalase crystals exhibit a positive surface charge (Zeta potential = +20 mV) in water at pH 5 (catalase isoelectric point = 5.8), as determined by electrophoretic mobility measurements.

A tapping mode atomic force microscopy (AFM) image of a catalase crystal, approximately $8 \times 12 \mu\text{m}$ in size, is shown in Fig. 2(a). Next, the first polyelectrolyte layer, poly(styrenesulfonate) (PSS), which bears an opposite charge to the positively charged crystal surface, was added to the crystal suspension and allowed to self-assemble onto the crystal (Fig. 1). At this stage the enzyme crystal surface charge was reversed to a Zeta potential of -30 mV, indicating the successful adsorption of PSS. Repeating alternating depositions of poly(allylaminehydrochloride) (PAH) and PSS produced crystals with alternating positive (+20 mV) and negative (-30 mV) surface potentials, respectively. These data clearly demonstrate recharging the surface.

In order to verify that the enzyme crystals are successfully coated with polymer multilayer shells, a fluorescently labelled polyelectrolyte (fluorescein isothiocyanate - (FITC) - PAH) was substituted for each alternate PAH deposition in the build up process. The fluorescence, as seen under a fluorescence microscope, originates only from the surface of the polymer coated enzyme crystals (Fig. 2b). The fluorescence signal was found to increase systematically with an increasing number of fluorescent layers. No noticeable change in size or shape of the crystals were observed with the polymer multilayer shell coating. Further, the polymer-coated enzymes could be stored for at least 30 days at 4°C without any noticeable change in

- 20 -

morphology. These results show that enzyme crystals can be encapsulated within a polymer multilayer capsule via the step-wise and regular assembly of oppositely charged polymers, and that the crystal size and shape is retained upon their coating.

5

Exposure of the polymer multilayer-encapsulated enzyme crystals to a solution of $\text{pH} > 6$ resulted in the polymer capsule assuming a more spherical shape (Fig. 3a). Similar morphology changes were observed for other coated crystals, although perfectly spherical capsules were not always
10 observed (as seen in Fig. 3a). The morphology change of the polymer capsules at $\text{pH} > 6$ is attributed to the solubilization of the enzyme crystal, which occurs because the polymer multilayers are permeable to the mobile ions in the solution phase.

15 Evidence that the enzyme was encapsulated within the polymer capsules was obtained by deliberately rupturing the polymer shells. The polymer multilayer capsules were found to partially rupture upon exposure to alkaline solutions of $\text{pH} > 11$. An optical micrograph image of shell rupture is displayed in Fig. 3b. Soon after shell wall rupture, solubilized enzyme is
20 expelled from the interior of the capsule. The expulsion of the enzyme is caused by the osmotic pressure between the interior and exterior of the polymer capsules. Video microscopy verifies that the solubilized enzyme is expelled upon exposure to solutions of $\text{pH} > 11$ as a result of capsule rupture. These data confirm that the solubilized enzyme is entrapped within
25 the polymer capsules.

The catalase activity was measured after its solubilization and release from the polymer capsules. A recovered specific activity of 97% was obtained, compared with 100% for the uncoated catalase. This shows that the
30 polymer coating of the catalase crystals proceeds without causing any significant loss of enzyme activity.

- 21 -

Fig. 4 shows representative AFM and TEM images of the air-dried polymer capsules, obtained after exposing the polymer-coated enzyme crystals to an oxidizing solution (deproteinizer). The enzymes are decomposed by the deproteinizing treatment, allowing the expulsion of their fragment constituents from the interior by permeating the polymer capsule walls. The polymer multilayer capsules remain intact, as can be seen in the images. The drying process (evaporation of the aqueous content by air-drying) induces a number of folds and creases in the polymer capsules. The shells are also flattened and some spreading is noticed; the diameters of the dried polymer capsules are approximately 20 μm . The texture of the shells is characteristic of the polyelectrolyte film, although some residual catalase can be seen in the capsules. From the AFM image for the polymer capsule, it can be deduced from the lowest height dimensions (35 nm), equivalent to twice the polymer capsule wall thickness, that the average thickness per polyelectrolyte layer is approximately 2 nm (the enzyme crystal templates were coated with eight layers). Cross-section TEM images and confocal microscopy show that hydrated polymer capsules maintain their spherical shape in solution, although spreading and creasing is observed on drying, as seen here after removal of the enzyme and subsequent drying.

20

10. Juni 1999

- 22 -

Claims

1. A process for preparing coated crystals comprising the steps:
 - (a) providing a dispersion of crystal template particles in a solvent
5 and
 - (b) coating said particles with a multilayer comprising alternating layers of oppositely charged polyelectrolytes and/or nanoparticles.
- 10 2. The process of claim 1, wherein said crystal template particles are bio-crystals.
3. The process of claim 1 or 2, wherein said crystal particles are protein
15 crystals, peptide crystals, nucleic acid crystals, lipid based crystals, carbohydrate crystals or crystals from low molecular weight materials.
4. The process of claim 3, wherein said protein crystals are selected
20 from antibody crystals, enzyme crystals, virus capsid protein crystals, S-layer protein crystals, glycoprotein crystals, receptor protein crystals and cytosolic protein crystals.
5. The process of claim 1, wherein said crystal template particles are
25 selected from the group consisting of crystalline bio-material, crystalline organic material, crystalline inorganic material or mixtures thereof.
6. The process of claim 5, wherein the crystalline or organic material is
30 selected from crystalline drugs, crystalline vitamin, crystalline nutrients, crystalline hormones, crystalline growth factors, crystalline pesticides and crystalline antibiotics.

- 23 -

7. The process of any one of claims 1 to 6, wherein the crystal template is a single crystal or an amorphous crystal material.
8. The process of any of claims 1 to 7, wherein said template particles have an average diameter of 500 μm or less.
9. The process of claim 8, wherein said template particles have an average diameter of 50 μm or less.
10. The process of any one of claims 1 to 9, wherein said polyelectrolytes are linear molecules.
11. The process of any one of claims 1 to 10, wherein said polyelectrolytes are selected from inorganic, organic and biological polyelectrolytes and mixtures thereof.
12. The process of claim 10, wherein the organic polyelectrolyte is a polymer selected from biodegradable polymers, fluorescently labelled polymers, conducting polymers, liquid crystal polymers, photoconducting polymers, photochromic polymers, and copolymers and/or mixtures thereof.
13. The process of claim 10, wherein the biological polyelectrolyte is a polymer selected from polyamino acids, polycarbohydrates, polynucleotides and modified biopolymers.
14. The process of claim 10, wherein the inorganic polyelectrolyte is a polymer based on polysilanes, polysilanoles, polyphosphazanes, polysulfazenes, polysulfides and polyphosphates.
15. The process of any one of claims 1 to 14, wherein said nanoparticles have an average diameter of from 1 to 100 nm.

- 24 -

16. The process of any one of claims 1 to 15, wherein said nanoparticles are selected from inorganic, organic and biological particles or mixtures thereof.

5 17. The process of claim 16, wherein said nanoparticles are selected from particles which provide targeting properties.

18. The process of claim 16 or 17, wherein said nanoparticles are particles having magnetic properties.

10 19. The process of claim 16 or 17, wherein said nanoparticles are immunoglobulins or receptor ligands.

15 20. The process of any one of claims 16 to 19, wherein the inorganic nanoparticles are ceramic particles, magnetic particles, magneto-optical particles, nitridic ceramic particles, carbidic ceramic particles, metallic particles, and/or sulfur or selenium-containing particles.

20 21. The process of any one of claims 16 to 19, wherein the organic or biological nanoparticles are macromolecules and/or targeting molecules.

25 22. The process of any one of the preceding claims, wherein said solvent is selected from aqueous solvents, organic solvents and mixed aqueous/organic solvents.

23. The process of any one of the preceding claims further comprising the step:
(c) at least partially solubilizing the encapsulated crystals.

30 24. The process of claim 23, wherein said solubilization is carried out by adjustment of solvent, pH, temperature and/or salt conditions.

- 25 -

25. The process of any one of the preceding claims further comprising the step:
- (d) rupturing the polyelectrolyte/nanoparticle shell.
- 5 26. The process of any one of the claims 1 to 24 further comprising the step:
- (e) at least partially disintegrating encapsulated biomolecules.
- 10 27. Coated particle having a core which is a crystal template particle and a multilayer shell comprising alternating layers of oppositely charged polyelectrolytes and/or nanoparticles.
- 15 28. Coated particle having a core comprising an at least partially solubilized crystal template particle and a multilayer shell comprising alternating layers of oppositely charged nanoparticles and/or polyelectrolytes.
- 20 29. The particle of claim 27 or 28 having an average diameter of 50 μm or less.
30. Hollow shell obtainable by disintegrating the template particle of the coated particle of claim 27, 28 or 29.
- 25 31. Use of the particle according to any one of claims 27 to 29 as a system for targeted delivery and/or controlled release of crystallizable biomolecules.

10. Juni 1999

- 26 -

Abstract

The invention refers to a new process for preparing coated crystals by
5 coating crystal template particles with alternating layers of oppositely
charged polyelectrolytes and/or nanoparticles.

10

15

20


25

30

home/mh/anm/20077PEP 10.06.1999

THIS PAGE BLANK (USPTO)

10. Juni 1999 EPO-Munich
55
10. Juni 1999



10. Juni 1999

10. Juni 1999







Figure 2







THIS PAGE BLANK (USPTO)